-+ 0.00%
-+ 0.00%
-+ 0.00%

NeuroSense Therapeutics Announces Promising Phase 2b PARADIGM Study Results Showing Significant Survival Advantage for ALS Drug PrimeC

Reuters·09/04/2025 13:03:09

Please log in to view news